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1. Introduction
The first description of medication-related osteonecrosis of the jaw (MRONJ) associated with bisphosphonates was published by
Marx in 2003 [1]. MRONJ is defined as bone exposed to the oral cavity for at least eight weeks in the maxillofacial region for at least 8
weeks in patients at-risk due to prior or current medication therapy. Over the years, additional medications have been implicated
MRONJ beyond bisphosphonates and interdisciplinary strategies for screening and management have shown a reduction in the rate of
MRONJ [2]. Despite the increased attention and research, the pathophysiology of MRONJ remains poorly understood. Most cases and
reviews published thus far have occurred in patients previously diagnosed with malignant and metastatic disease as bisphosphonate
use in these patients reduces the risk of adverse skeletal events such as fractures [3]. We present a case where treatment of MRONJ
based on clinical parameters resulted in a subsequent diagnosis of occult B-cell lymphoproliferative disorder.
2. Case report
A 79-year-old female presented to the Department of Oral & Maxillofacial Surgery for evaluation of a lesion of the anterior
mandible. The patient reported history of non-insulin dependent diabetes mellitus, hypertension, hyperlipidemia, and osteoporosis.
Her osteoporosis was treated by her primary care physician with alendronate 70mg weekly for a total duration of five years. Her
diabetes was well controlled and she denied history of tobacco use or smoking. She reported dental extractions two years prior to
facilitate the fabrication of a complete mandibular denture. Seven months prior to her presentation to our clinic, she developed a large
submandibular swelling which resulted in spontaneous submental drainage. She reported she was only treated with antibiotics and the
swelling resolved with persistent drainage at a submental site. For the seven months since her infection and initial drainage, she
reported persistent drainage of fluid from underneath her chin for which she would use gauze dressings as needed. She denied recent
fever, chills, nausea, vomiting, difficulty breathing, or dysphagia.
On clinical exam, she was normocephalic with no appreciable facial asymmetry. In the submental region, she had a slight nontender swelling with a noted depression associated with granulation tissue (Fig. 1a). The granulation tissue was associated with a
chronic fistula which had minimal seropurulent drainage. Intraorally, she was completely edentulous on the maxilla and mandible. She
had no swelling of the floor of mouth or posteriorly towards the oropharynx. On the lingual aspect of the left mandible, there was an
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Fig. 1. Preoperative Photos A) Worms-eye view of orocutaneous fistula. B) Intraoral view of exposed bone on left mandible C) Intraoral view of
orocutaneous fistula D) Patient provided photo of previous swelling months prior to presentation.

area of exposed bone 1cm by 1cm in dimension (Fig. 1b). On the right mandible, there were punctate fistula with seropurulent
drainage (Fig. 1c). At that time, cultures were taken of the drainage intraorally and extraorally. A CT Maxillofacial was performed
which demonstrated multiple areas of bone erosion involving both sides of the mandible. The erosion of the left mandible was greater
than right and there was associated cortical destruction with surrounding sclerosis of the adjacent bone without periosteal reaction.
Additionally, there was a linear sequestration along the medial aspect of the left body of mandible (Fig. 2). Based on her history and
clinical presentation, she was given a diagnosis of Stage III MRONJ. The patient was started on amoxicillin/clavulanic acid therapy and
scheduled for surgical intervention. The cultures returned from the extraoral and intraoral sites were both polymicrobial in nature
representing skin and oral flora respectively. Ultimately, the patient was taken to the operating room where she had segmental
resection of the involved portion of the anterior mandible with placement of custom designed patient specific plate for mandibular
reconstruction (Fig. 3). Given the chronicity of the infection and the fistula, the decision was made not to attempt reconstruction of the
area with bone graft at the same time as resection. She was admitted for inpatient management post-operatively. She was evaluated by
the Department of Infectious Disease and a peripherally inserted central catheter was placed in anticipation of an extended duration of
intravenous antibiotics. The cultures from surgery grew Enterobacter cloacae. She tolerated the procedure and was discharged to home
two days after the procedure with intravenous ertapenem therapy for a planned 6-week duration. Histopathologic analysis performed
on the resection specimen revealed viable and non-viable bone with an unanticipated finding of chronic plasmocytic infiltration. The
specimen showed a predominantly plasmocytic inflammatory infiltrate arranged in “sheets” in some areas (Fig. 4). The increased
number of plasma cells and their growth pattern was concerning for a plasma cell dyscrasia. In situ hybridization for kappa and lambda
light chain was noncontributory due to prior decalcification of the specimen. The findings prompted referral to the Department of
Hematology/Oncology for further workup. A full skeletal series and long bone survey was performed which revealed no lytic lesions. A
complete blood count with differential was within normal limits. The beta-2 microglobulin was negative. SPEP demonstrated faint
bands in IgG and lambda. The free light chain ratio was elevated in both the serum and urine analyses. The serum kappa/lambda ratio
was high at 3.19 and the urine kappa/lambda ratio was 82.27. Ultimately, a bone marrow biopsy was performed. The core biopsy
showed mild increase in small mature B-cells. Immunohistochemistry for CD20 and PAX-5 shows a predominance of B cells involving
5–10% of marrow (Fig. 5). Concurrent flow cytometry detected an CD5þ/CD23 þ clonal B-cell population with kappa light chain
restriction. This phenotype was consistent with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). A concurrent
FISH study identified a deletion of RB1 and concurrent karyotype demonstrated no abnormalities (Fig. 6). The patient was ultimately
diagnosed with CD5þ B cell lymphoproliferative disorder. She continued active surveillance with oncology for transformation or
change of disease. From a surgical standpoint, the patient healed without issue and demonstrated resolution of chronic infection and
draining fistula post operatively (Figs. 7 and 8).
3. Discussion
Although MRONJ is related to antiresorptive therapy for many different diseases including blood dyscrasias, it is infrequently found
concomitant with the disease process. There have been a few case reports of concurrent metastatic disease, including multiple
myeloma and breast cancer, in resection specimens for MRONJ [4–6]. Carlson et al. [7] performed a large retrospective study to
identify patients treated for MRONJ with resection on IV bisphosphonate therapy for cancer with metastatic disease found in the
resection specimens. The prevalence of cancer detected in the MRONJ specimens of this group was 5.3%, with multiple myeloma as the
predominant associated metastasis [7]. In the setting of cancer with metastases to bone and lytic lesions of multiple myeloma, IV
bisphosphonate therapy is supported in various guidelines to reduce the rate of pathologic fractures and morbidity from interventions
2
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Fig. 2. Pre-operative radiographs. A CT maxillofacial bony window with representative axial (A), coronal (B), and sagittal cuts. D) Pano
ramic radiograph.

A)

B)

Fig. 3. Intraoperative photos of resected specimen from posterior (A) and superior (B) views.

A)

B)

Fig. 4. Histopathological evaluation with hematoxylin and eosin stains. A) Biopsy specimen showing necrotic bony trabeculae, with empty lacunae
in the top of the frame compared with viable osteocytes in the lower right corner. B) Bone marrow core biopsy showing a lymphoid aggregate
comprised of monomorphic population of small mature lymphocytes. Note trilineage hematopoiesismm in background (H&E, original magnifica
tion 400�).

A)

B)

Fig. 5. Immunohistochemical evaluation of bone marrow biopsy specimens. A) Pax-5 stain highlights B-cells in the interstitium and loose aggre
gates in bone marrow core biopsy B) CD5 stain in the bone marrow core biopsy shows similar distribution to B-cells (original magnification 400�).
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Fig. 6. Fluoresence In-Situ Hybridization of bone marrow biopsy demonstrating positive deletion of RB1.

for bone pain [3,8]. The current American Association of Oral and Maxillofacial Surgeons (AAOMS) position paper on MRONJ con
siders the role of anti-angiogenic medications in disease progression in addition to anti-resorptive medications such as bisphospho
nates [2]. Since the position paper update, there have been a few case reports of MRONJ from disease modifying antirheumatic drugs
(DMARDs) and immunosuppressive medications used after organ transplant [9,10]. A recent case series demonstrates a case of MRONJ
in the setting of treatment of chronic lymphocytic leukemia with antiresorptive agents and targeted therapy with tyrosine kinase
inhibitors [11]. Aghaloo and Tetradis [12] reported a case series of six patients with MRONJ without antiangiogenic or antiresorptive
medications, rather the use of various anti-rheumatic agents with Stage II and III MRONJ.
Interestingly, methotrexate and rituximab are associated with iatrogenic lymphoproliferative disorders [13,14]. Our patient was
ultimately diagnosed with a CD5þ B cell lymphoproliferative disorder as she did not meet the diagnostic criteria for chronic lym
phocytic leukemia and she demonstrated deletion of RB1, a frequent chromosomal abnormality found in B-cell lymphoproliferative
disorders [15]. Her presentation was similar to monoclonal B-cell lymphocytosis; however, she did not meet the diagnostic criteria due
to the presence of chronic infection [16]. Monoclonal B-cell lymphocytosis is considered a precursor condition to chronic lymphocytic
leukemia similar to monoclonal gammopathy of undetermined significant (MGUS) is a precursor condition to multiple myeloma [17,
18]. Evidence suggests that precursor conditions such as MGUS which were initially thought to not have clinical implications are
associated with increased rates of adverse skeletal events [19].
Our patient had a clear history of bisphosphonate-use and met the established criteria for MRONJ. However, her bisphosphonate
use was limited to the oral bisphosphonate agent alendronate. Nitrogen-containing bisphosphontes such as alendronate, have been
shown to trigger the release of pro-inflammatory mediators such as IL-6 and TNFa from osteoclasts. An in vivo study demonstrated
bisphosphonate-treated osteoclasts survive longer than untreated osteoclasts as they are not subject to the cytotoxic effects of natural
killer cells. The longer survival time may contribute to chronic inflammation in areas of bone turnover [20]. A large retrospective study
of patients with chronic oral bisphosphonate therapy identified a low prevalence of MRONJ at 0.10% [21]. Other factors identified to
increase the risk of MRONJ with oral bisphosphonate-use includes dental extraction, smoking, poorly-controlled diabetes, athero
sclerosis, and steroid-use [22]. The additional risk factors for our patient only included history of dental extractions. Given the low
prevalence of MRONJ with oral bisphosphonates and case reports that have implicated medications associated with iatrogenic lym
phoproliferative disorders in MRONJ, is it unclear how our patient’s undiagnosed lymphoproliferative disorder may have contributed
to her development of stage III MRONJ. Of note, the plasmocytic infiltration was seen outside of the area of necrotic bone and was
included in the specimen due to segmental resection. In a review of margin analysis for MRONJ, Qaisi and Montague [23] discuss the
need for representative samples of the resected bone to evaluate for underlying pathology contributing to bone destruction. In
addition, there is difficulty in establishing a clear margin or additional pathologic processes with pathology specimens from conser
vative debridements [23]. It is possible in our case the association of the clonal population in the MRONJ resection specimen was
serendipitous and unrelated to her MRONJ progression. If so, the treatment allowed her to obtain a diagnosis before the manifestation
of symptoms and enter active surveillance to monitor for transformation. However, there is evidence in the form of case series and case
reports reviewed to suggest that lymphoproliferative disorders may play a yet undermined role in some forms of MRONJ. MRONJ in
the setting immunosuppressant agents could represent an intramedullary manifestation of iatrogenic immunodeficiency-associated
lymphoproliferative disorders. In much the same way that intravenous and oral bisphosphonate regimens have different risk pro
files for the development of MRONJ, it could be that different forms of lymphoproliferative disorders factor differently into the MRONJ
scenario [2,24]. Additional research is needed to elucidate possible interplay between lymphoproliferative disorders and osteonecrosis
of the jaw.
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Fig. 7. Post-Operative Photos A) Worms-eye view of extraoral scar from mandibular resection B) Intraoral view of mandibular resection site C)
Intraoral view of healed orocutaneous fistula site.

6

Oral and Maxillofacial Surgery Cases 5 (2019) 100099

R. Diecidue et al.

A)
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Fig. 8. Post-operative radiographs. A CBCT maxillofacial A) 3-D rendering of bony window B) Panoramic radiograph after 4 months.
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